RİCKY D TURGEON, TRANA HUSSAİNİ, NİLUFAR PARTOVİ, SİEGFRİED R ERB, ROLAND NADOR, VLADİMİR MARQUEZ AZALGARA, ERİC YOSHİDA
Experimental and Clinical Transplantation - 2017;15(6):693-695
Hepatopulmonary syndrome and portopulmonary hypertension are complications of portal hypertension with opposing mechanisms that can coexist. Moderate portopulmonary hypertension, which is a contra - indication to a liver transplant, must be managed with pulmonary vasodilators to normalize pulmonary arterial pressures before a transplant listing. Con - comitant hepatopulmonary syndrome complicates the management of portopulmonary hypertension, as pulmonary vasodilators can theoretically exacerbate the intrapulmonary dilatation believed to cause hepatopulmonary syndrome. We describe a case of a post-liver transplant patient with concomitant hepatopulmonary syndrome and portopulmonary hypertension safely treated with sildenafil.
